You are leaving GSKpro website

The information you are about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information.

Continue

Go back

NP-AU-NA-WCNT-190017

Product menu

Choose indication

Severe Eosinophilic Asthma (SEA)

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

NUCALA patient types, severe asthma, nasal polyps and comorbid with eosinophil background

NUCALA: battle tested in eosinophilic disease.*1

Proven results across SEA, CRSwNP and EPGA.1

NUCALA (mepolizumab) is the only monoclonal antibody that targets IL-5 across multiple eosinophilic diseases.*1,2

NUCALA has robust safety and tolerability data across multiple indications.*1

Women in an apron standing in front of a food truck

NUCALA for severe eosinophilic asthma (SEA)

NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and older.1

LEARN MORE
Man in apron with a dog in grooming salon

NUCALA for chronic rhinosinusitis with Nasal Polyps (CRSwNP)

NUCALA is indicated as an add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps with an inadequate response to intranasal corticosteroids.1

LEARN MORE

Need help with this product?

Request a contact

Have a representative contact you

Live Chat

Speak with a live representative

Stay Informed

Sign up for email from GSK

Footnotes

*SEA, CRSwNP, EGPA.1

CRSwNP, chronic rhinosinusitis with nasal polyps; EGPA, eosinophilic granulomatosis with polyangiitis; SEA, severe eosinophilic asthma.

References

  1. NUCALA Product Information
  2. Severe Asthma Toolkit. Monoclonal antibodies [updated 2022 Oct 27; accessed 2023 Mar 3] 

PBS Information: The 100 mg vial and 100 mg/mL pen are listed on the PBS as a
section 100 item for uncontrolled severe asthma. Refer to the PBS schedule for full
authority information. The 100 mg/mL pen is listed on the PBS as a section 100 item for
CRSwNP. Refer to the PBS schedule for full authority information. NUCALA is not
listed on the PBS for EGPA.

Please review Product Information before prescribing. Product Information can be
accessed at www.gsk.com.au/nucala

For information on GSK products or to report an adverse event involving a GSK
product, please contact GSK Medical Information on 1800 033 109.

For more information on this product please
contact us.

Trade marks are owned by or licensed to the GSK group of companies.

©2024 GSK group of companies or its licensor.

PM-AU-MPL-WCNT-230004
Date of approval: April 2024